Transforming Dupuytren's Contracture Treatment with Live Demonstration
Keenova Therapeutics plc is gearing up for an innovative demonstration that is set to elevate the standards of Dupuytren's contracture treatment. This event is especially monumental as it represents the first live procedure conducted at the American Association for Hand Surgery (AAHS) Annual Meeting, occurring over two days. The audience will gain first-hand insights into the treatment process of Dupuytren's contracture, which can significantly impact many patients.
The live demonstration will incorporate XIAFLEX, recognized as the only FDA-approved nonsurgical approach for treating Dupuytren's contracture when a cord is detectable. Attendees will witness the injection process on the first day, followed by an engaging session on finger extension on the subsequent day. Such events not only showcase procedural techniques but also highlight the crucial connection between healthcare providers and patient outcomes.
Innovative Two-Day Treatment Experience
The demonstration is not merely a presentation; it’s an opportunity for medical professionals to observe the real-time effects of XIAFLEX treatment. Dr. Mark Elzik will be leading the treatment of James Renzas, a patient familiar with various techniques including prior surgical interventions. By treating Renzas's proximal interphalangeal (PIP) joint in his pinky finger, Dr. Elzik will illustrate the efficacy of the XIAFLEX injection and provide in-depth commentary on its administration.
As the medical community increasingly seeks hands-on experiences, the two-day format allows ample exploration of both practical and theoretical aspects of the procedure. Observers will not only witness the injection but will also receive explanations regarding patient selection and injection techniques, leading to a deeper understanding of the applicative and strategic elements involved in the treatment.
Engaging the Healthcare Community
Keenova is committed to equipping healthcare providers with the tools they need to deliver expert care. During the meeting, attendees will have the chance to interact with the Mixed Reality Injection Simulator. This state-of-the-art technology offers an immersive experience, allowing hand specialists to refine their skills by practicing on physical models paired with digital simulations.
Additionally, Keenova will offer new injector training, facilitating a learning environment where medical professionals can develop their expertise in administering XIAFLEX effectively. These innovative educational experiences exemplify Keenova's dedication to enhancing the knowledge and skills of those caring for individuals with Dupuytren's contracture.
Understanding Dupuytren's Contracture
Dupuytren's contracture is a progressive condition characterized by a buildup of collagen in the hand, which creates cord-like bands that draw fingers towards the palm. Affected individuals often struggle with daily tasks as the condition worsens. The cumulative impact of Dupuytren's contracture affects an estimated thirteen million Americans, emphasizing the need for effective treatments like XIAFLEX.
The condition remains longstanding, potentially leading to challenges in work and personal life as fingers become increasingly harder to straighten. Keenova’s advancements present hope for patients seeking non-surgical alternatives, reshaping treatment expectations within the medical community.
About Keenova Therapeutics
Keenova Therapeutics aims to be a leader in developing innovative treatments for rare or neglected conditions, striving to improve the quality of life for all patients. The company focuses on an extensive portfolio that spans various therapeutic fields, catering to significant unmet needs, including in areas like orthopedics and immunology.
Headquartered in Dublin, Ireland, Keenova has a robust manufacturing presence in the United States, ensuring a strong supply chain that supports its mission. The company is dedicated to expanding accessibility to its products, enhancing patient outcomes through reliable therapies.
Frequently Asked Questions
What is Dupuytren's contracture?
Dupuytren's contracture is a condition where collagen builds up in the hand, forming cords that can pull fingers toward the palm, making them hard to straighten.
What is XIAFLEX?
XIAFLEX is the first FDA-approved nonsurgical treatment for Dupuytren's contracture, specifically for cases where a palpable cord is present.
What can attendees expect from the live demonstration?
Healthcare providers can expect to see a real treatment procedure, including an injection and follow-up techniques, alongside explanations from the treating physician.
How does the Mixed Reality Injection Simulator work?
This simulator offers a hands-on experience, allowing participants to practice on physical models while interacting with digital content to enhance their technique.
Why is Keenova's work significant?
Keenova's innovations in treatment approaches and patient care set a new standard for managing Dupuytren's contracture and highlight the importance of non-surgical options.
